Category Archives: Biotech
By Jill Wechsler | Published: March 7, 2014
Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.
By Pharm Exec | Published: February 28, 2014
While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.
By Julian Upton | Published: February 26, 2014
Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
By Guest Blogger | Published: February 19, 2014
by Tom Norton I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide […]
By Pharm Exec | Published: February 14, 2014
The Affordable Care Act (ACA) has sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward. Within this uncertain market, what is obvious is that the industry is in the midst of significant transition. Critical drivers of this change are largely macroeconomic; policy […]